Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer

Cancer

Volumn 116, Issue 11, 2010, Pages 2590-2595

  Hoffman, Karen E ^a,b   Chen, Ming Hui ^c   Moran, Brian J ^d   Braccioforte, Michelle H ^d   Dosoretz, Daniel ^d   Salenius, Sharon ^e   Katin, Michael J ^e   Ross, Rudi ^e   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d Prostate Cancer Foundation of Chicago   (United States)

^e 521St Century Oncology ^*  (United States)

Author keywords

Androgen suppression therapy; Brachytherapy; Elderly; High risk prostate cancer; Radiation therapy

Indexed keywords

BICALUTAMIDE; CESIUM 131; FLUTAMIDE; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; SEMINAL VESICLE; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 77952853768     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24974     Document Type: Article

References (24)

1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008;26:211-218.
2. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009;73(5 suppl):S4-S10.
3. Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179:1797-1803; discussion 1803.
4. Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology. 2003;62:860-865. (Pubitemid 37421232)
5. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683-2693. (Pubitemid 44917546)
6. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613-621. (Pubitemid 30321303)
7. Sung JC, Kabalin JN, Terris MK. Prostate cancer detection, characterization, and clinical outcomes in men aged 70 years and older referred for transrectal ultrasound and prostate biopsies. Urology. 2000;56:295-301.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
9. D'Amico AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol. 2009;27:3923-3928.
10. Greene FL. Prostate. In: Fleming JD, Page FL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002: 309-316.
11. Hollander M, Wolfe DA. The One-Way Layout. In: Nonparametric Statistical Methods. 2nd ed. New York: John Wiley & Sons; 1999:189-269.
12. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
13. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of causespecific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
15. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21:3318-3327.
16. Merrick GS, Wallner KE, Galbreath RW, et al. Prostate brachytherapy in men > or =75 years of age. Int J Radiat Oncol Biol Phys. 2008;72:415-420.
17. Blood PA, Pickles T. The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer. Radiat Oncol. 2007;2:17.
18. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-1154.
19. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984. (Pubitemid 40638368)
20. Nanda A, D'Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. BJU Int. 2008;102:1366-1368.
21. Roach M 3rd. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol. 2007;183(spec no. 2):26-28.
22. [No authors listed] Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235-246.
23. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer [serial online]. Cochrane Database Syst Rev. 2002;(1):CD003506.
24. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-181. (Pubitemid 351969301)